Boston Scientific backs MiRus with $1.5B stake, eyes exclusive TAVR deal
Boston Scientific announced a $1.5 billion investment for about 34% equity in MiRus and secured an exclusive option to acquire MiRus’ SIEGEL balloon-expandable transcatheter aortic valve replacement (TAVR) system, built on a proprietary nickel-free rhenium alloy. The device features dry porcine tissue leaflets and a nitric oxide-coated rhenium frame with high radial strength, and it is designed for precise placement via an 8 French expandable sheath. MiRus has launched the STAR pivotal trial evaluating three valve sizes in up to 1,025 patients. The deal is expected to be immaterial to 2026 EPS, with Boston Scientific able to move to 100% ownership via additional payments totaling up to $3 billion upon milestones.